Testosterone Cypionate

FDA ApprovedStrong Evidence
Written by dr-sarah-chen|Reviewed by Healthier Rx Editorial Board|Updated 2026-03-25|3 min read
Quick Facts
TypeTestosterone Replacement Therapy
FDA StatusFDA Approved
Evidence LevelStrong Evidence
Typical Dose100-200mg/week
Frequency1-2x per week
Cycle LengthOngoing (TRT)
Key GoalsHormone Optimization, Muscle Growth, Sexual Health

How It Works

Testosterone Cypionate is a long-acting ester of testosterone, the primary male sex hormone. When injected intramuscularly or subcutaneously, the cypionate ester slowly releases testosterone into the bloodstream over 7-10 days.

Testosterone binds to androgen receptors throughout the body, driving protein synthesis, bone mineral density, red blood cell production, cognitive function, mood regulation, and sexual function. In hypogonadal men, TRT restores testosterone to physiological levels.

Benefits

  • Restoration of normal testosterone levels and symptom resolution
  • Increased lean muscle mass and strength
  • Improved bone mineral density
  • Enhanced libido and sexual function
  • Improved mood, energy, and cognitive function
  • Reduced body fat percentage

Side Effects

  • Hematocrit elevation (polycythemia) — most common, requires monitoring
  • Estradiol elevation — may require aromatase inhibitor management
  • Acne — mild to moderate in some patients
  • Testicular atrophy — if used without HCG
  • Fertility suppression — exogenous testosterone suppresses spermatogenesis
  • Injection site reactions — pain, swelling at injection site

Dosing Protocol

ParameterDetails
Starting Dose100-120mg/week
Maintenance Dose100-200mg/week (adjusted by labs)
Frequency2x/week (split dose) for stable levels
AdministrationIntramuscular (vastus lateralis, deltoid) or subcutaneous
Lab Check6-8 weeks after starting, then every 6-12 months

Frequently Asked Questions

References

  1. Testosterone therapy in men with hypogonadismThe Journal of Clinical Endocrinology & Metabolism (2018). PMID: 29562364

    Endocrine Society clinical practice guideline for testosterone therapy in men with hypogonadism.

  2. Testosterone replacement therapy and cardiovascular riskJAMA (2023). PMID: 37428480

    TRAVERSE trial showing TRT does not increase major cardiovascular events in hypogonadal men.

Compare Testosterone Cypionate

Protocols Featuring Testosterone Cypionate

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new treatment or protocol. Read our full medical disclaimer.